Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

Sponsor
Sun Yat-sen University
Study ID
NCT01912443
Status
Unknown

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.

Study Details

To assess the safety profile of bevacizumab in combination with chemotherapy for the treatment of metastatic colorectal cancer

Key Dates

First listed
Jul 31, 2013
Start date
Aug 31, 2013
Status verified
Apr 2014
Primary completion
Aug 31, 2017

Study Design

Enrollment
600 participants (estimated)

Arms

  • Arm: Bevacizumab Plus Chemotherapy

Primary Outcome Measure

Incidence, nature and severity of adverse events of special interest [ Time Frame: Four years ]

Central Contacts

Related Studies